- Home
- BOLT vs MRKR Comparison
BOLT vs MRKR Comparison
Compare BOLT & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- MRKR
- Stock Information
- Founded
- BOLT 2015
- MRKR N/A
- Country
- BOLT United States
- MRKR United States
- Employees
- BOLT N/A
- MRKR N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- MRKR Health Care
- Exchange
- BOLT Nasdaq
- MRKR Nasdaq
- Market Cap
- BOLT 10.4M
- MRKR 11.6M
- IPO Year
- BOLT 2021
- MRKR N/A
- Fundamental
- Price
- BOLT $6.17
- MRKR $1.06
- Analyst Decision
- BOLT Buy
- MRKR Strong Buy
- Analyst Count
- BOLT 3
- MRKR 3
- Target Price
- BOLT $47.50
- MRKR $13.17
- AVG Volume (30 Days)
- BOLT 33.8K
- MRKR 325.1K
- Earning Date
- BOLT 11-11-2025
- MRKR 11-13-2025
- Dividend Yield
- BOLT N/A
- MRKR N/A
- EPS Growth
- BOLT N/A
- MRKR N/A
- EPS
- BOLT N/A
- MRKR N/A
- Revenue
- BOLT $4,167,000.00
- MRKR $5,388,071.00
- Revenue This Year
- BOLT N/A
- MRKR N/A
- Revenue Next Year
- BOLT N/A
- MRKR $9.35
- P/E Ratio
- BOLT N/A
- MRKR N/A
- Revenue Growth
- BOLT N/A
- MRKR 44.55
- 52 Week Low
- BOLT $4.59
- MRKR $0.81
- 52 Week High
- BOLT $14.36
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- BOLT 63.23
- MRKR 55.45
- Support Level
- BOLT $5.13
- MRKR $0.85
- Resistance Level
- BOLT $6.20
- MRKR $0.96
- Average True Range (ATR)
- BOLT 0.32
- MRKR 0.07
- MACD
- BOLT 0.07
- MRKR 0.03
- Stochastic Oscillator
- BOLT 87.19
- MRKR 69.64
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.